Novel mechanisms of HIV protease inhibitor resistance

Current Opinion in HIV and AIDS

Volumn 3, Issue 6, 2008, Pages 627-632

  Nijhuis, Monique ^a   Van Maarseveen, Noortje M ^a   Verheyen, Jens ^b   Boucher, Charles A B ^a,c  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b UNIVERSITY OF COLOGNE   (Germany)

^c ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Gag cleavage sites; Protease inhibitor therapy; Resistance

Indexed keywords

DARUNAVIR; GAG PROTEIN; LOPINAVIR; LOPINAVIR PLUS RITONAVIR; PROTEINASE; PROTEINASE INHIBITOR; RITONAVIR; VIRUS ENZYME;

AMINO ACID SUBSTITUTION; ANTIVIRAL RESISTANCE; ANTIVIRAL THERAPY; DRUG MECHANISM; DRUG TREATMENT FAILURE; ENZYME ACTIVATION; ENZYME MECHANISM; ENZYME STRUCTURE; ENZYME SUBSTRATE; FRAMESHIFT MUTATION; GENE INSERTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN FUNCTION; REVIEW; SITE DIRECTED MUTAGENESIS; STRUCTURE ACTIVITY RELATION; VIRUS MUTATION; VIRUS RESISTANCE;

EID: 67649576660     PISSN: 1746630X     EISSN: 17466318     Source Type: Journal    
DOI: 10.1097/COH.0b013e3283136cd9     Document Type: Review

References (51)

1. Kohl NE, Emini EA, Schleif WA, et al. Active human immunodeficiency virus protease is required for viral infectivity. Proc Natl Acad Sci U S A 1988; 85:4686-4690.
2. Jacks T, Power MD, Masiarz FR, et al. Characterization of ribosomal frame-shifting in HIV-1 gag-pol expression. Nature 1988; 331:280-283.
3. Shehu-Xhilaga M, Crowe SM, Mak J. Maintenance of the Gag/Gag-Pol ratio is important for human immunodeficiency virus type 1 RNA dimerization and viral infectivity. J Virol 2001; 75:1834-1841.
4. Dulude D, Berchiche YA, Gendron K, et al. Decreasing the frameshift efficiency translates into an equivalent reduction of the replication of the human immunodeficiency virus type 1. Virology 2006; 345:127-136.
5. Krausslich HG, Ingraham RH, Skoog MT, et al. Activity of purified biosynthetic proteinase of human immunodeficiency virus on natural substrates and synthetic peptides. Proc Natl Acad Sci U S A 1989; 86:807-811.
6. Wiegers K, Rutter G, Kottler H, et al. Sequential steps in human immunodeficiency virus particle maturation revealed by alterations of individual Gag polyprotein cleavage sites. J Virol 1998; 72:2846-2854.
7. Pettit SC, Moody MD, Wehbie RS, et al. The p2 domain of human immunodeficiency virus type 1 Gag regulates sequential proteolytic processing and is required to produce fully infectious virions. J Virol 1994; 68:8017-8027.
8. Pettit SC, Henderson GJ, Schiffer CA, et al. Replacement of the P1 amino acid of human immunodeficiency virus type 1 Gag processing sites can inhibit or enhance the rate of cleavage by the viral protease. J Virol 2002;76:10226-10233.
9. Nijhuis M, van Maarseveen NM, Lastere S, et al. A novel substrate-based HIV-1 protease inhibitor drug resistance mechanism. PLoS Med 2007; 4:e36. This study describes the in-vitro selection of protease inhibitor-resistant viruses with mutations in the Gag NC/p1 cleavage site in the absence of resistance mutations in protease.
10. Wlodawer A, Miller M, Jaskólski M, et al. Conserved folding in retroviral proteases: crystal structure of a synthetic HIV-1 protease. Science 1989; 245:616-621.
11. Navia MA, Fitzgerald PMD, McKeever BM, et al. Three dimensional structure of aspartyl protease from human immunodeficiency virus HIV-1. Nature 1989;337:615-620.
12. Croteau G, Doyon L, Thibeault D, et al. Impaired fitness of human immunodeficiency virus type 1 variants with high-level resistance to protease inhibitors. J Virol 1997; 71:1089-1096.
13. Nijhuis M, Schuurman R, de Jong D, et al. Increased fitness of drug resistant HIV-1 protease as a result of acquisition of compensatory mutations during suboptimal therapy. AIDS 1999; 13:2349-2359.
14. Mammano F, Trouplin V, Zennou V, et al. Retracing the evolutionary pathways of human immunodeficiency virus type 1 resistance to protease inhibitors: Virus fitness in the absence and in the presence of drug. J Virol 2000; 74:8524-8531.
15. Quinones-Mateu ME, Arts EJ. HIV-1 Fitness: implications for drug resistance, disease progression an global epidemic evolution. In: Kuiken C, Foley B, Hahn B, et al., editors. HIV sequence compendium 2001. Theoretical Biology and Biophysics Group, Los Alamos National Laboratory; 2001.
16. Mammano F, Petit C, Clavel F. Resistance-associated loss of viral fitness in human immunodeficiency virus type 1: phenotypic analysis of protease and gag coevolution in protease inhibitor-treated patients. J Virol 1998; 72:7632-7637.
17. Zhang Y-M, Imamichi H, Imamichi T, et al. Drug resistance during indinavir therapy is caused by mutations in the protease gene and in its gag substrate cleavage sites. J Virol 1997; 71:6662-6670.
18. Doyon L, Croteau G, Thibeault D, et al. Second locus involved in human immunodeficiency virus type 1 resistance to protease inhibitors. J Virol 1996;70:3763-3769.
19. Maguire MF, Guinea R, Griffin P, et al. Changes in human immunodeficiency virus type 1 Gag at positions L449 and P453 are linked to I50V protease mutants in vivo and cause reduction of sensitivity to amprenavir and improved viral fitness in vitro. J Virol 2002; 76:7398-7406.
20. Peters S, Munoz M, Yerly S, et al. Resistance to nucleoside analog reverse transcriptase inhibitors mediated by human immunodeficiency virus type 1 p6 protein. J Virol 2001; 75:9644-9653.
21. Gallego O, de Mendoza C, Corral A, et al. Changes in the human immunodeficiency virus p7-p1-p6 gag gene in drug-naive and pretreated patients. J Clin Microbiol 2003; 41:1245-1247.
22. Whitehurst N, Chappey C, Petropoulos C, et al. Polymorphisms in p1-p6/p6* of HIV type 1 can delay protease autoprocessing and increase drug susceptibility. AIDS Res Hum Retroviruses 2003; 19:779-784.
23. Paulus C, Hellebrand S, Tessmer U, et al. Competitive inhibition of human immunodeficiency virus type-1 protease by the Gag-Pol transframe protein. J Biol Chem 1999; 274:21539-21543.
24. Tessmer U, Krausslich HG. Cleavage of human immunodeficiency virus type 1 proteinase from the N-terminally adjacent p6* protein is essential for efficient Gag polyprotein processing and viral infectivity. J Virol 1998; 72:3459-3463.
25. Paulus C, Ludwig C, Wagner R. Contribution of the Gag-Pol transframe domain p6* and its coding sequence to morphogenesis and replication of human immunodeficiency virus type 1. Virology 2004; 330:271-283.
26. Ludwig C, Leiherer A, Wagner R. Importance of protease cleavage sites within and flanking human immunodeficiency virus type 1 transframe protein p6* for spatiotemporal regulation of protease activation. J Virol 2008; 82:4573-4584.
27. Doyon L, Payant C, Brakier Gingras L, et al. Novel Gag-Pol frameshift site in human immunodeficiency virus type 1 variants resistant to protease inhibitors. J Virol 1998; 72:6146-6150.
28. Girnary R, King L, Robinson L, et al. Structure-function analysis of the ribosomal frameshifting signal of two human immunodeficiency virus type 1 isolates with increased resistance to viral protease inhibitors. J Gen Virol 2007; 88:226-235.
29. Prado JG, Wrin T, Beauchaine J, et al. Amprenavir-resistant HIV-1 exhibits lopinavir cross-resistance and reduced replication capacity. AIDS 2002; 16:1009-1017.
30. De Meyer S, Azijn H, Fransen E, et al. The pathway leading to TMC114 resistance is different for TMC114 compared with other protease inhibitors. Antivir Ther 2006; 11:S24.
31. Koh Y, Nakata H, Maeda K, et al. Novel bis- tetrahydrofuranylurethane-containing nonpeptidic protease inhibitor (PI) UIC-94017 (TMC114) with potent activity against multi-PI-resistant human immunodeficiency virus in vitro. Antimicrob Agents Chemother 2003; 47:3123-3129.
32. Heilek-Snyder G, Kohli A, Cammack N, et al. In vitro cross resistance profile of RO033-4649 against a panel of multiply-substituted protease inhibitor resistant viruses: role of common protease resistance mutations. Antivir Ther 2003; 8:S21.
33. Nijhuis M, Wensing AM, Bierman W, et al. A novel genetic pathway involving L76V and M46I leading to lopinavir/r resistance. Antivir Ther 2007; 12:S140.
34. Callebaut C, Stray K, Tsai L, et al. In vitro HIV-1 resistance selection to GS-8374, a novel phosphonate protease inhibitor: comparison with lopinavir, atazanavir and darunavir. Antivir Ther 2007; 12:S18.
35. Gatanaga H, Suzuki Y, Tsang H, et al. Amino acid substitutions in Gag protein at noncleavage sites are indispensable for the development of a high multitude of HIV-1 resistance against protease inhibitors. J Biol Chem 2002; 277:5952-5961.
36. Nijhuis M, van Maarseveen NM, de Jong D, et al. Substitutions within Gag but outside the cleavage sites can cause protease inhibitor resistance. Antivir Ther 2006; 11:S149.
37. Bally F, Martinez R, Peters S, et al. Polymorphism of HIV type 1 gag p7/p1 and p1/p6 cleavage sites: clinical significance and implications for resistance to protease inhibitors. AIDS Res Hum Retroviruses 2000; 16:1209-1213.
38. Verheyen J, Schweitzer F, Harrer E, et al. HIV p7/p1 cleavage-site mutations are selected by the immune system and/or by antiretroviral therapy. Antivir Ther 2006; 13:A71.
39. Verheyen J, Litau E, Sing T, et al. Compensatory mutations at the HIV cleavage sites p7/p1 and p1/p6-gag in therapy-naive and therapy-experienced patients. Antivir Ther 2006; 11:879-887. This study shows accumulation of mutations in the HIV Gag NC/p1 and p1/p6 cleavage sites during protease inhibitor therapy
40. Verheyen J, Altmann A, Knops E, et al. Relevance of HIV gag cleavage site mutations in failures of protease inhibitor therapies. Antivir Ther 2008; 13:A53.
41. Verheyen J, Kücherer C, Litau E, et al. Cleavage site mutations in transmitted primary resistant HIV of therapy-naive patients. 5th European HIV Drug Resistance Workshop; 28-30 March 2007; Cascais, Portugal; 2007.
42. Dierynck I, De Meyer S, Cao-Van K, et al. Impact of Gag cleavage site mutations on virological response to darunavir/ritonavir in treatment-experienced patients in POWER 1, 2 and 3. Antivir Ther 2007; 12:S23. This study demonstrates that Gag cleavage site mutations may affect the virological response to a boosted protease inhibitor regimen.
43. Garcia-Diaz A, Fox Z, Dragsted UB, et al. Treatment-emergent gag cleavage site mutations during virological failure of ritonavir-boosted protease inhibitors. Antivir Ther 2008; 13:A80.
44. Ueda T, Myint L, Shiino T, et al. Analysis of interference and co-evolution between protease inhibitor resistant mutations and gag mutations. Antivir Ther 2005; 10:S116.
45. Dam E, Faudon JL, Launay O, et al. Compensation of resistance-associated loss of replicative capacity by Gag is restricted to the NC-p1-p6 domains. Antivir Ther 2007; 12:S117.
46. Malet I, Roquebert B, Dalban C, et al. Association of Gag cleavage sites to protease mutations and to virological response in HIV-1 treated patients. J Infect 2007; 54:367-374.
47. Nijhuis M, Schipper PJ, King M, et al. Changes in HIV Gag and protease cannot explain persistent viraemia in the majority of patients failing first-line lopinavir/ritonavir therapy. Antivir Ther 2007; 12:S146.
48. Quercia R, Dam E, Descamps D, et al. Discordant effects of Gag cleavage site mutations on the IC50 of protease inhibitors and on HIV replicative capacity. 15th Conference on Retroviruses and Opportunistic Infections; 3-6 February 2008; Boston, MA; 2008.
49. Parry CM, Kohli A, Pillay D. Gag-protease inter-relationships in drug-resistance and viral fitness. Antivir Ther 2008; 13:A81.
50. Verheyen J, Hamouda O, Somogy O, et al. Increase of cleavage site mutations in the German HIV-1 seroconverter study over time. Antivir Ther 2007; 12:S145.
51. Ait-Khaled M, Xu F, Tisdale M, et al. Absence of protease mutations upon virological failure of first-line fosamprenavir/ritonavir is not explained by the alternative selection of p7/p1 or p1/p6 Gag cleavage site mutations. Antivir Ther 2006; 11:S148.